These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19208456)

  • 21. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
    Tubiana R; Gomard E; Fleury H; Gougeon ML; Mouthon B; Picolet H; Katlama C
    AIDS; 1997 May; 11(6):819-20. PubMed ID: 9143616
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV.
    Bourinbaiar AS; Jirathitikal V; Metadilogkul O; Sooksathan P; Paiboon P; Aemsri S; Prapai P; Chaodon K
    J Clin Virol; 2004 Dec; 31 Suppl 1():S55-62. PubMed ID: 15567095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
    Loret EP; Darque A; Jouve E; Loret EA; Nicolino-Brunet C; Morange S; Castanier E; Casanova J; Caloustian C; Bornet C; Coussirou J; Boussetta J; Couallier V; Blin O; Dussol B; Ravaux I
    Retrovirology; 2016 Apr; 13():21. PubMed ID: 27036656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attempts to cure and prevent HIV/AIDS in central Nigeria between 1997 and 2002: opening a way to a vaccine-based solution to the problem?
    Abalaka JO
    Vaccine; 2004 Sep; 22(29-30):3819-28. PubMed ID: 15364427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
    Pialoux G; Hocini H; Pérusat S; Silberman B; Salmon-Ceron D; Slama L; Journot V; Mathieu E; Gaillard C; Petitprez K; Launay O; Chêne G;
    Vaccine; 2008 May; 26(21):2657-66. PubMed ID: 18068876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIT study produces more questions than answers.
    TreatmentUpdate; 1998 Jul; 10(5):1-2. PubMed ID: 11365623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
    Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.
    Coulaud IP; Gougeon ML; Gomard E; Descamps D; Lebon P; Aboulker JP; Bizzini B; Zagury D
    AIDS; 1997 Jun; 11(7):937-8. PubMed ID: 9189226
    [No Abstract]   [Full Text] [Related]  

  • 31. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.
    Kloverpris H; Karlsson I; Bonde J; Thorn M; Vinner L; Pedersen AE; Hentze JL; Andresen BS; Svane IM; Gerstoft J; Kronborg G; Fomsgaard A
    AIDS; 2009 Jul; 23(11):1329-40. PubMed ID: 19528789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV hope ride on therapeutic vaccine.
    AIDS Read; 2005 Jul; 15(7):332. PubMed ID: 16044573
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines. From Brazil and France: a vaccine against HIV may lower viral load.
    TreatmentUpdate; 2005; 17(1):10-1. PubMed ID: 17228459
    [No Abstract]   [Full Text] [Related]  

  • 36. Vaccines for HIV--Remune returns.
    TreatmentUpdate; 2004 Oct; 16(6):3. PubMed ID: 17219678
    [No Abstract]   [Full Text] [Related]  

  • 37. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 38. Vaccines. Study finds Remune reduces risk of virologic failure.
    TreatmentUpdate; 2004 Oct; 16(6):3-4. PubMed ID: 17225281
    [No Abstract]   [Full Text] [Related]  

  • 39. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.